Glucose-dependent insulinotropic polypeptide (GIP)

Glucose-dependent insulinotropic polypeptide (GIP)

Background: Glucose-dependent insulinotropic polypeptide (GIP) was the first incretin identified and plays an essential role in the maintenance of glucose tolerance in healthy humans. Until recently GIP had not been developed as a therapeutic and thus has been overshadowed by the other incretin, glu...

Full description

Bibliographic Details
Main Authors: Timo D. Müller, Alice Adriaenssens, Bo Ahrén, Matthias Blüher, Andreas L. Birkenfeld, Jonathan E. Campbell, Matthew P. Coghlan, David D'Alessio, Carolyn F. Deacon, Stefano DelPrato, Jonathan D. Douros, Daniel J. Drucker, Natalie S. Figueredo Burgos, Peter R. Flatt, Brian Finan, Ruth E. Gimeno, Fiona M. Gribble, Matthew R. Hayes, Christian Hölscher, Jens J. Holst, Patrick J. Knerr, Filip K. Knop, Christine M. Kusminski, Arkadiusz Liskiewicz, Guillaume Mabilleau, Stephanie A. Mowery, Michael A. Nauck, Aaron Novikoff, Frank Reimann, Anna G. Roberts, Mette M. Rosenkilde, Ricardo J. Samms, Philip E. Scherer, Randy J. Seeley, Kyle W. Sloop, Christian Wolfrum, Denise Wootten, Richard D. DiMarchi, Matthias H. Tschöp
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:Molecular Metabolism
Subjects:
Diabetes
GLP-1
GIP
Incretin
Insulin
Obesity
Online Access:http://www.sciencedirect.com/science/article/pii/S2212877825000250

Internet

http://www.sciencedirect.com/science/article/pii/S2212877825000250

Similar Items